COVID-19-associated secondary hemophagocytic lymphohistiocytosis requiring hematopoietic cell transplant

eJHaem

article

Jacob R. Greenmyer¹  Kirk D Wyatt²  Sam Milanovich²  Mira A. Kohorst³  Asmaa Ferdjallah³ 

[1] Pediatric and Adolescent Medicine, Mayo Clinic;Pediatric Hematology and Oncology, Sanford Health;Pediatric Hematology and Oncology, Mayo Clinic

关键词: hematology;    infection;    pediatrics;    stem cell transplantation;    thrombocytopenia;   

DOI  :  10.1002/jha2.456

来源: Wiley

【 摘 要 】

Coronavirus disease 2019 (COVID-19) infection causes a variety of extrapulmonary complications in pediatric patients. Multisystem inflammatory syndrome and hemophagocytic lymphohistiocytosis (HLH) are related to hypercytokinemia in COVID-19 patients. HLH is a disorder of exaggerated inflammation resulting in a cytokine storm and unrestricted hemophagocytosis. HLH can be primary (familial) or secondary (acquired). Secondary HLH (sHLH) can occur in patients with rheumatologic, oncologic, or infectious diseases. The link between COVID-19 and HLH has been reported in pediatric patients. Here we report a case of a pediatric patient who developed refractory sHLH secondary to COVID-19 infection and required a hematopoietic cell transplant for the cure.

【 授权许可】

Unknown